MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Botulinum toxin: Clinical applications: other"

  • 2023 International Congress

    Botulinum neurotoxin in FXTAS-related tremor: a “successful” case report

    AT. Cimmino, P. Sanginario, AR. Bentivoglio, P. Calabresi, M. Petracca, G. Di Lazzaro (Rome, Italy)

    Objective: We report the case of a man affected by FXTAS, presenting with disabling tremor who experienced a significant and long-lasting benefit from botulinum neurotoxin…
  • 2023 International Congress

    Development of a Vibro-Tactile Stimulation wristband for targeted therapy of Focal Task Specific Dystonias

    S. Arjun, A. Singh, H. Singh, R. Jain, I. Ahuja (Chandigarh, India)

    Objective: To design and develop a wristband that provides vibro-tactile stimulation as a sensory geste/trick for patients with FTSDs. The device will offer different frequencies…
  • 2023 International Congress

    Diaphragmatic flutter – when the diaphragm does not obey

    M. Danis (Trnava, Slovakia)

    Objective: clonic twitching of the rectus abdominis muscle and tonic spasm of the diaphragm Background: 61-year-old patient seeking medical help for difficulties lasting about a…
  • 2023 International Congress

    Real-world retrospective safety analysis of onabotulinumtoxinA for the treatment of patients with concurrent cervical dystonia and chronic migraine

    C. Rhyne, K. Martinez, J. Stoilova, A. Patel, K. Becker Ifantides, R. Singh, I. Yushmanova, M. Sadeghi, S. Battucci, G. Forde (Chicago, USA)

    Objective: To assess the real-world safety of onabotulinumtoxinA (onabotA) for the concomitant treatment of cervical dystonia (CD) and chronic migraine (CM). Background: In the United…
  • 2023 International Congress

    Hemifacial Spasm: Recent experience in a movement disorders reference center in Chile

    P. Salles, X. Pizarro, P. Chana, E. Betancur, I. Sanchez (Santiago, Chile)

    Objective: To analyze the demographic characteristics of patients with HFS and their response to different BoNT at the center for movement disorders CETRAM in Santiago,…
  • 2023 International Congress

    Botulinum toxin-A in head and upper extremities tremor. A hand-made option

    H. Shehata, M. Shehata, M. Basheer, A. Elmazny, N. Shalaby (Cairo, Egypt)

    Objective: This was a 24-week open-label study to assess the role of BoNT-A injections for various types of hand and head tremor Background: Focal treatment…
  • 2023 International Congress

    Validation and psychometric properties of the Thai version of the hemifacial spasm grading questionnaire (HFS score) for physician-assessed clinical involvement and patient-reported health-related quality of life: a prospective observational study

    ���N. Likhitwitayawuid, Y. Pitakpatapee, W. Saengphatarachai, P. Srivanitchapoom (Bangkok, Thailand)

    Objective: The primary aim was translation to thai and cognitive debriefing of the thai version of the hfs score in patients with hfs. The secondary…
  • 2023 International Congress

    SYNCHRONIZE: Real-world retrospective safety analysis in patients treated with onabotulinumtoxinA for more than one therapeutic indication

    A. Patel, G. Forde, K. Martinez, A. Mayadev, B. Brucker, K. Becker Ifantides, R. Singh, M. Nelson, I. Yushmanova, S. Battucci, C. Rhyne (Overland Park, USA)

    Objective: Report real-world safety of onabotulinumtoxinA used concomitantly for multiple therapeutic indications. Background: Therapeutic onabotulinumtoxinA is approved in the US for 12 indications, some of…
  • 2023 International Congress

    IncobotulinumtoxinA to treat sialorrhea in Parkinson’s disease: a real-life study: 4-year interim results

    B. Bergmans, N. Winter, V. Schotte, N. Sys, L. Delameilleure, E. van Massenhove, H. Couckuyt, M. van Zandijcke (Bruges, Belgium)

    Objective: We evaluate the long-term efficacy and safety of incobotulinumtoxinA injections in advanced Parkinson’s disease (PD) patients suffering from sialorrhea. Background: Sialorrhea is frequently a…
  • 2023 International Congress

    Putting the patient’s voice at the venter: Tracking the impact of botulinum neurotoxin therapy for movement disorders using patient-reported outcomes

    S. Samadzadeh, V. Koska, J. Waskönig, PJ. Jouvenal, SGM. Meuth, HH. Hefter, PA. Albrecht (Düsseldorf, Germany)

    Objective: To investigate how patient reported outcomes (PROs) perform to document the effects of a botulinum neurotoxin (BONT) treatment of movement disorders in the clinical…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 12
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Patients with Essential Tremor Live Longer than their Relatives
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley